Shire's New Product Portfolio Delivers Strong Quarterly P...(months to September 30 2008 were $8.6mil...)

Date:10/29/2008

months to September 30, 2008 were $8.6 million, a decrease of 16% (2007: $10.2 million). The impact of foreign exchange movements has contributed 10% to the reported decline; excluding unfavorable foreign exchange movements there has been a decrease of 6% compared to the same period in 2007.

OTHER

Other royalties are primarily in respect of REMINYL and REMINYL XL (known as RAZADYNE and RAZADYNE ER in the US), a product marketed worldwide (excluding the UK and the Republic of Ireland) by Janssen Pharmaceutical N.V. ("Janssen"), an affiliate of Johnson & Johnson. Shire has exclusive marketing rights in the UK and the Republic of Ireland.

In the US, patent infringement litigation brought by Synaptech and Janssen against several ANDA filers culminated in a trial in Delaware in 2007. Following a decision on August 28, 2008 which rendered the relevant patent invalid, generic versions of RAZADYNE were permitted to enter the US market.

Sales of the REMINYL/RAZADYNE range, for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer's type, continue to grow in most countries however the entry of generics into the US market has severely decreased sales in that region. This decline was expected and is included in our forecasts.

Litigation proceedings relating to RAZADYNE, RAZADYNE ER, REMINYL and REMINYL XL are ongoing. Further information on these litigations can be found in our filings with the SEC, including our Annual Report on Form 10-K for the year to December 31, 2007.

4. Financial details

Cost of product sales

% of

% of product product

2008 sales 2007 sales

$m $m

--------- --------- --------- ---------

<
'/>"/>

SOURCE Shire Plc Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related biology technology :

1. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
2. PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery
3. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
4. GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
5. Consumers Looking to Sustainable Food Production to Feed Global Population
6. Contour Products Introduces Groundbreaking Sleep Apnea, Respiratory and Ergonomic Body Comfort Pillows at Medtrade; Self-Explanatory Products Serve Customer Needs, Expand Retailers DME Offerings
7. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
8. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
9. Ventria Expands Lactoferrin Production
10. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
11. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space